Final Closing of MTIP Fund 1
Basel, April 2017 – MTIP MedTech Innovation Partners AG has closed its first fund significantly above expectation at CHF 60 million.
After its launch a year ago, MTIP’s first fund closed at a total of just under CHF 60 million. Due to strong investor demand this is considerably higher than the CHF 40 million targeted at the outset. "A first fund of this magnitude is exceptional in the industry and a great success for our investors and us," explains Dr. Christoph Kausch, CEO of MTIP. The capital comes from institutional investors such as pension funds and family offices, hospitals, foundations and qualified private individuals. MTIP will use this fund to invest in a portfolio of around 10 startups in the medical technology sector. The aim is to support these businesses and to facilitate their further development into successful companies. Having invested in two startups (Coramaze and Reactive Robotics) already, additional investments are expected later this year as MTIP’s project pipeline is looking promising with additional attractive opportunities. "MTIP’s involvement in the innovation landscape, from university research to practical use in hospitals and an understanding of the relevant MedTech players’ portfolio strategies are important success factors in our business model", emphasises board president Dr. Felix Grisard. In the selection process of companies MTIP places a clear focus on health economic benefits and patient-relevant innovations. MTIP builds sustainable investments that facilitate improved health care at home and abroad and combine economic success with added value for the community.
For more information please contact:
Dr. Christoph Kausch
Chief Executive Officer
Phone: +41 61 551 02 50
MTIP MedTech Innovation Partners AG